Pier 88 Investment Partners LLC Buys New Holdings in Natera, Inc. (NASDAQ:NTRA)

Pier 88 Investment Partners LLC acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 6,190 shares of the medical research company's stock, valued at approximately $875,000.

A number of other institutional investors have also modified their holdings of NTRA. LRI Investments LLC purchased a new position in shares of Natera during the 4th quarter valued at approximately $29,000. Rakuten Securities Inc. raised its position in shares of Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after acquiring an additional 119 shares during the last quarter. ORG Partners LLC acquired a new position in shares of Natera during the first quarter worth about $32,000. Covestor Ltd raised its stake in Natera by 42.7% in the fourth quarter. Covestor Ltd now owns 531 shares of the medical research company's stock valued at $84,000 after buying an additional 159 shares during the period. Finally, True Wealth Design LLC boosted its holdings in shares of Natera by 39.6% in the 4th quarter. True Wealth Design LLC now owns 631 shares of the medical research company's stock valued at $100,000 after purchasing an additional 179 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Down 0.5%

NASDAQ NTRA traded down $0.69 during mid-day trading on Tuesday, hitting $139.95. The stock had a trading volume of 186,274 shares, compared to its average volume of 1,409,787. The company has a market cap of $19.11 billion, a price-to-earnings ratio of -95.31 and a beta of 1.73. Natera, Inc. has a 52-week low of $92.14 and a 52-week high of $183.00. The company has a 50 day simple moving average of $160.09 and a 200 day simple moving average of $158.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.09. The firm had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. Natera's quarterly revenue was up 36.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.56) earnings per share. As a group, equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on NTRA shares. Barclays increased their target price on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Piper Sandler upped their target price on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. UBS Group increased their price objective on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Finally, Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to MarketBeat, Natera has a consensus rating of "Moderate Buy" and a consensus price target of $184.63.

Insider Activity

In related news, Director Gail Boxer Marcus sold 4,299 shares of the firm's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total transaction of $719,480.64. Following the sale, the director directly owned 8,118 shares in the company, valued at $1,358,628.48. This trade represents a 34.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $166.77, for a total transaction of $500,310.00. Following the completion of the sale, the insider directly owned 130,205 shares in the company, valued at approximately $21,714,287.85. The trade was a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,655 shares of company stock valued at $7,964,464 over the last three months. 7.60% of the stock is currently owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.